Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment
Shares of Japan's Sumitomo Pharma fell over 12% on the back of profit-taking after a specialist panel endorsed its iPS cell-based therapy for Parkinson's disease.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
